Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fabrizio Gasparini

Showing results (1-10 of 65) with videos related to

Pageof 7
Sort By:
Drug News & Perspectives|August 31, 2004
mGlu5 receptor antagonists: a novel class of anxiolytics?Will Spooren, Fabrizio Gasparini
The Journal of Pharmacology and Experimental Therapeutics|June 14, 2003
Group II metabotropic and alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA)/kainate glutamate receptors regulate the deficit in brain reward function associated with nicotine withdrawal in ratsPaul J Kenny, Fabrizio Gasparini, Athina Markou
Psychopharmacology|February 28, 2002
Nicotine potentiation of brain stimulation reward reversed by DH beta E and SCH 23390, but not by eticlopride, LY 314582 or MPEP in ratsAmanda A Harrison, Fabrizio Gasparini, Athina Markou
Current Opinion in Pharmacology|January 12, 2002
Allosteric modulators of group I metabotropic glutamate receptors: novel subtype-selective ligands and therapeutic perspectivesFabrizio Gasparini, Rainer Kuhn, Jean-Philippe Pin
Parkinson'S Disease|July 16, 2013
Metabotropic glutamate receptors for Parkinson's disease therapyFabrizio Gasparini, Thérèse Di Paolo, Baltazar Gomez-Mancilla
Psychopharmacology|April 19, 2003
The mGluR5 antagonist MPEP decreased nicotine self-administration in rats and miceNeil E Paterson, Svetlana Semenova, Fabrizio Gasparini, et al.
Current Opinion in Drug Discovery & Development|August 30, 2008
mGluR5 antagonists: discovery, characterization and drug developmentFabrizio Gasparini, Graeme Bilbe, Baltazar Gomez-Mancilla, et al.
International Journal of Molecular Sciences|July 14, 2023
Central and Peripheral Inflammation in Mild Cognitive Impairment in the Context of Alzheimer's DiseaseInès Schmidt-Morgenroth, Philippe Michaud, Fabrizio Gasparini, et al.
Drug Discovery Today|December 24, 2003
Non-nicotinic neuropharmacological strategies for nicotine dependence: beyond bupropionJohn F Cryan, Fabrizio Gasparini, Gino van Heeke, et al.
Current Topics in Behavioral Neurosciences|February 11, 2011
Metabotropic glutamate receptors: their therapeutic potential in anxietyWill Spooren, Anne Lesage, Hilde Lavreysen, et al.
Pageof 7

Showing results (1-10 of 65) with videos related to

Sort By:
Pageof 7
Drug News & Perspectives|August 31, 2004
mGlu5 receptor antagonists: a novel class of anxiolytics?Will Spooren, Fabrizio Gasparini
The Journal of Pharmacology and Experimental Therapeutics|June 14, 2003
Group II metabotropic and alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA)/kainate glutamate receptors regulate the deficit in brain reward function associated with nicotine withdrawal in ratsPaul J Kenny, Fabrizio Gasparini, Athina Markou
Psychopharmacology|February 28, 2002
Nicotine potentiation of brain stimulation reward reversed by DH beta E and SCH 23390, but not by eticlopride, LY 314582 or MPEP in ratsAmanda A Harrison, Fabrizio Gasparini, Athina Markou
Current Opinion in Pharmacology|January 12, 2002
Allosteric modulators of group I metabotropic glutamate receptors: novel subtype-selective ligands and therapeutic perspectivesFabrizio Gasparini, Rainer Kuhn, Jean-Philippe Pin
Parkinson'S Disease|July 16, 2013
Metabotropic glutamate receptors for Parkinson's disease therapyFabrizio Gasparini, Thérèse Di Paolo, Baltazar Gomez-Mancilla
Psychopharmacology|April 19, 2003
The mGluR5 antagonist MPEP decreased nicotine self-administration in rats and miceNeil E Paterson, Svetlana Semenova, Fabrizio Gasparini, et al.
Current Opinion in Drug Discovery & Development|August 30, 2008
mGluR5 antagonists: discovery, characterization and drug developmentFabrizio Gasparini, Graeme Bilbe, Baltazar Gomez-Mancilla, et al.
International Journal of Molecular Sciences|July 14, 2023
Central and Peripheral Inflammation in Mild Cognitive Impairment in the Context of Alzheimer's DiseaseInès Schmidt-Morgenroth, Philippe Michaud, Fabrizio Gasparini, et al.
Drug Discovery Today|December 24, 2003
Non-nicotinic neuropharmacological strategies for nicotine dependence: beyond bupropionJohn F Cryan, Fabrizio Gasparini, Gino van Heeke, et al.
Current Topics in Behavioral Neurosciences|February 11, 2011
Metabotropic glutamate receptors: their therapeutic potential in anxietyWill Spooren, Anne Lesage, Hilde Lavreysen, et al.
Pageof 7